CN112125881B - 4-吡啶取代酞嗪酮类化合物、其制备方法、药物组合物及用途 - Google Patents
4-吡啶取代酞嗪酮类化合物、其制备方法、药物组合物及用途 Download PDFInfo
- Publication number
- CN112125881B CN112125881B CN202010600646.9A CN202010600646A CN112125881B CN 112125881 B CN112125881 B CN 112125881B CN 202010600646 A CN202010600646 A CN 202010600646A CN 112125881 B CN112125881 B CN 112125881B
- Authority
- CN
- China
- Prior art keywords
- formula
- group
- compound
- acid
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 phthalazinone compound Chemical class 0.000 title claims abstract description 64
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 135
- 238000006243 chemical reaction Methods 0.000 claims description 62
- 150000003839 salts Chemical class 0.000 claims description 46
- 239000000243 solution Substances 0.000 claims description 42
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 39
- 125000000217 alkyl group Chemical group 0.000 claims description 36
- 125000000623 heterocyclic group Chemical group 0.000 claims description 25
- 229940024606 amino acid Drugs 0.000 claims description 24
- 235000001014 amino acid Nutrition 0.000 claims description 24
- 150000001413 amino acids Chemical class 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 125000002947 alkylene group Chemical group 0.000 claims description 21
- 239000007787 solid Substances 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 20
- 125000000539 amino acid group Chemical group 0.000 claims description 19
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical group C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 15
- 125000003545 alkoxy group Chemical group 0.000 claims description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 14
- 239000001257 hydrogen Substances 0.000 claims description 14
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 13
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- IDIDJDIHTAOVLG-VKHMYHEASA-N S-methylcysteine Chemical compound CSC[C@H](N)C(O)=O IDIDJDIHTAOVLG-VKHMYHEASA-N 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- 150000002148 esters Chemical class 0.000 claims description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 11
- 229960003767 alanine Drugs 0.000 claims description 11
- 235000004279 alanine Nutrition 0.000 claims description 11
- 125000005842 heteroatom Chemical group 0.000 claims description 11
- 125000006239 protecting group Chemical group 0.000 claims description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 9
- 239000002585 base Substances 0.000 claims description 9
- 238000009833 condensation Methods 0.000 claims description 9
- 230000005494 condensation Effects 0.000 claims description 9
- 150000007530 organic bases Chemical class 0.000 claims description 9
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 claims description 8
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical group [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 8
- 235000013922 glutamic acid Nutrition 0.000 claims description 8
- 239000004220 glutamic acid Substances 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 125000006574 non-aromatic ring group Chemical group 0.000 claims description 7
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 claims description 6
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 6
- 239000004475 Arginine Substances 0.000 claims description 6
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 6
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 claims description 6
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 claims description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 6
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 6
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 6
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 6
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 6
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims description 6
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 claims description 6
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 6
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 claims description 6
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 6
- 239000004472 Lysine Substances 0.000 claims description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 6
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims description 6
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 6
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 6
- IDIDJDIHTAOVLG-UHFFFAOYSA-N S-methyl-L-cysteine Natural products CSCC(N)C(O)=O IDIDJDIHTAOVLG-UHFFFAOYSA-N 0.000 claims description 6
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 6
- 239000004473 Threonine Substances 0.000 claims description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 6
- 125000005529 alkyleneoxy group Chemical group 0.000 claims description 6
- ZGUNAGUHMKGQNY-UHFFFAOYSA-N alpha-phenylglycine Chemical compound OC(=O)C(N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-UHFFFAOYSA-N 0.000 claims description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 6
- 235000009582 asparagine Nutrition 0.000 claims description 6
- 229960001230 asparagine Drugs 0.000 claims description 6
- 235000003704 aspartic acid Nutrition 0.000 claims description 6
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 235000013477 citrulline Nutrition 0.000 claims description 6
- 229960002173 citrulline Drugs 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 6
- 235000018417 cysteine Nutrition 0.000 claims description 6
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 claims description 6
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 claims description 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 6
- 235000004554 glutamine Nutrition 0.000 claims description 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 6
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 claims description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 6
- 229960000310 isoleucine Drugs 0.000 claims description 6
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 235000018977 lysine Nutrition 0.000 claims description 6
- 229930182817 methionine Natural products 0.000 claims description 6
- 235000006109 methionine Nutrition 0.000 claims description 6
- 229960003104 ornithine Drugs 0.000 claims description 6
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 6
- 229920006395 saturated elastomer Polymers 0.000 claims description 6
- NPDBDJFLKKQMCM-UHFFFAOYSA-N tert-butylglycine Chemical compound CC(C)(C)C(N)C(O)=O NPDBDJFLKKQMCM-UHFFFAOYSA-N 0.000 claims description 6
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 6
- 229960004295 valine Drugs 0.000 claims description 6
- 239000004474 valine Substances 0.000 claims description 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 5
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 5
- 239000004471 Glycine Substances 0.000 claims description 5
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 5
- 229910019142 PO4 Inorganic materials 0.000 claims description 5
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 5
- 229910000288 alkali metal carbonate Inorganic materials 0.000 claims description 5
- 150000008041 alkali metal carbonates Chemical group 0.000 claims description 5
- 125000004414 alkyl thio group Chemical group 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000000460 chlorine Substances 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000002950 monocyclic group Chemical group 0.000 claims description 5
- 239000010452 phosphate Substances 0.000 claims description 5
- 229960002429 proline Drugs 0.000 claims description 5
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 235000011054 acetic acid Nutrition 0.000 claims description 4
- 229910052783 alkali metal Inorganic materials 0.000 claims description 4
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 150000004820 halides Chemical class 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- 150000007522 mineralic acids Chemical class 0.000 claims description 4
- 150000007524 organic acids Chemical class 0.000 claims description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- 125000005270 trialkylamine group Chemical group 0.000 claims description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims description 4
- 229940127009 HBV antigen inhibitor Drugs 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 3
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 125000001188 haloalkyl group Chemical group 0.000 claims description 3
- 125000005059 halophenyl group Chemical group 0.000 claims description 3
- 208000006454 hepatitis Diseases 0.000 claims description 3
- 231100000283 hepatitis Toxicity 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 claims description 2
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 claims description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- IMPPGHMHELILKG-UHFFFAOYSA-N 4-ethoxyaniline Chemical compound CCOC1=CC=C(N)C=C1 IMPPGHMHELILKG-UHFFFAOYSA-N 0.000 claims description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 claims description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 150000001340 alkali metals Chemical class 0.000 claims description 2
- 150000001342 alkaline earth metals Chemical class 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 150000003863 ammonium salts Chemical class 0.000 claims description 2
- 125000000129 anionic group Chemical group 0.000 claims description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
- 229910052792 caesium Inorganic materials 0.000 claims description 2
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 125000002091 cationic group Chemical group 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 238000006482 condensation reaction Methods 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000004976 cyclobutylene group Chemical group 0.000 claims description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000004977 cycloheptylene group Chemical group 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000004956 cyclohexylene group Chemical group 0.000 claims description 2
- 125000004978 cyclooctylene group Chemical group 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000004979 cyclopentylene group Chemical group 0.000 claims description 2
- 125000004980 cyclopropylene group Chemical group 0.000 claims description 2
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
- 229940071870 hydroiodic acid Drugs 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 125000005647 linker group Chemical group 0.000 claims description 2
- 229910052744 lithium Inorganic materials 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 claims description 2
- 229910017604 nitric acid Inorganic materials 0.000 claims description 2
- 235000006408 oxalic acid Nutrition 0.000 claims description 2
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 claims description 2
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 235000019260 propionic acid Nutrition 0.000 claims description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 2
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 2
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 229910052712 strontium Inorganic materials 0.000 claims description 2
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 claims description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 150000001721 carbon Chemical group 0.000 claims 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 2
- 239000000375 suspending agent Substances 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 claims 2
- KRFHWYYZEDSECY-ZETCQYMHSA-N (2s)-2-(phenoxyamino)propanoic acid Chemical group OC(=O)[C@H](C)NOC1=CC=CC=C1 KRFHWYYZEDSECY-ZETCQYMHSA-N 0.000 claims 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 claims 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 claims 1
- 125000005916 2-methylpentyl group Chemical group 0.000 claims 1
- 125000005917 3-methylpentyl group Chemical group 0.000 claims 1
- 238000010511 deprotection reaction Methods 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 claims 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 1
- 125000004944 pyrazin-3-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 claims 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 abstract description 12
- 239000002777 nucleoside Substances 0.000 abstract description 9
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract description 9
- 238000001727 in vivo Methods 0.000 abstract description 3
- 239000003112 inhibitor Substances 0.000 abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 120
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- 239000012043 crude product Substances 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 16
- 230000002829 reductive effect Effects 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 14
- 125000003118 aryl group Chemical group 0.000 description 13
- 229940125904 compound 1 Drugs 0.000 description 13
- 229940079593 drug Drugs 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 238000010898 silica gel chromatography Methods 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 125000004104 aryloxy group Chemical group 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 8
- 101710132601 Capsid protein Proteins 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 208000002672 hepatitis B Diseases 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 101710142246 External core antigen Proteins 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 210000005259 peripheral blood Anatomy 0.000 description 6
- 239000011886 peripheral blood Substances 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- 239000004698 Polyethylene Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229960000980 entecavir Drugs 0.000 description 4
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 229960002449 glycine Drugs 0.000 description 4
- 125000005553 heteroaryloxy group Chemical group 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 230000004543 DNA replication Effects 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 3
- 150000001718 carbodiimides Chemical group 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 description 3
- 229960001627 lamivudine Drugs 0.000 description 3
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 238000000967 suction filtration Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 241000709721 Hepatovirus A Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 125000005027 hydroxyaryl group Chemical group 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 2
- 229940011051 isopropyl acetate Drugs 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-M isovalerate Chemical compound CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- CQRYARSYNCAZFO-UHFFFAOYSA-N salicyl alcohol Chemical compound OCC1=CC=CC=C1O CQRYARSYNCAZFO-UHFFFAOYSA-N 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- LCCZTROJRJFXNV-UHFFFAOYSA-N (2,6-difluoropyridin-3-yl)boronic acid Chemical compound OB(O)C1=CC=C(F)N=C1F LCCZTROJRJFXNV-UHFFFAOYSA-N 0.000 description 1
- BRZYSWJRSDMWLG-DJWUNRQOSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 1
- VTSRCHXIIMBAKT-WNQIDUERSA-N (2s)-2-aminopropanoic acid;2-chloropropane Chemical compound CC(C)Cl.C[C@H](N)C(O)=O VTSRCHXIIMBAKT-WNQIDUERSA-N 0.000 description 1
- SZXBQTSZISFIAO-ZETCQYMHSA-N (2s)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)OC(C)(C)C SZXBQTSZISFIAO-ZETCQYMHSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- FSAMVJAGJWGWTQ-UHFFFAOYSA-N 2-hexadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCOCCO FSAMVJAGJWGWTQ-UHFFFAOYSA-N 0.000 description 1
- ZQXSFZAMFNRZOQ-UHFFFAOYSA-N 2-methylpropan-2-ol;hydrate Chemical compound O.CC(C)(C)O ZQXSFZAMFNRZOQ-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- TZMJLUVODPVPDB-UHFFFAOYSA-N 3,6-dichloro-2H-phthalazine Chemical compound ClN1NC=C2C=CC(=CC2=C1)Cl TZMJLUVODPVPDB-UHFFFAOYSA-N 0.000 description 1
- LOQLDQJTSMKBJU-UHFFFAOYSA-N 4-(chloromethyl)benzonitrile Chemical compound ClCC1=CC=C(C#N)C=C1 LOQLDQJTSMKBJU-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- DGWFDTKFTGTOAF-UHFFFAOYSA-N P.Cl.Cl.Cl Chemical compound P.Cl.Cl.Cl DGWFDTKFTGTOAF-UHFFFAOYSA-N 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 1
- 229960003205 adefovir dipivoxil Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 229920000180 alkyd Polymers 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 229940124405 anti-hepatitis b virus drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- DMSZORWOGDLWGN-UHFFFAOYSA-N ctk1a3526 Chemical compound NP(N)(N)=O DMSZORWOGDLWGN-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- UOEFFQWLRUBDME-UHFFFAOYSA-N diethoxyphosphorylmethyl 4-methylbenzenesulfonate Chemical compound CCOP(=O)(OCC)COS(=O)(=O)C1=CC=C(C)C=C1 UOEFFQWLRUBDME-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- JCXLZWMDXJFOOI-WCCKRBBISA-N ethyl (2s)-2-aminopropanoate;hydrochloride Chemical compound Cl.CCOC(=O)[C@H](C)N JCXLZWMDXJFOOI-WCCKRBBISA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 125000003106 haloaryl group Chemical group 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- UKZCGMDMXDLAGZ-UHFFFAOYSA-M magnesium;2-methylpropane;bromide Chemical compound [Mg+2].[Br-].C[C-](C)C UKZCGMDMXDLAGZ-UHFFFAOYSA-M 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- IVRIRQXJSNCSPQ-UHFFFAOYSA-N propan-2-yl carbonochloridate Chemical compound CC(C)OC(Cl)=O IVRIRQXJSNCSPQ-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960005311 telbivudine Drugs 0.000 description 1
- IQFYYKKMVGJFEH-CSMHCCOUSA-N telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 description 1
- 229960004556 tenofovir Drugs 0.000 description 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 1
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 1
- DQWPFSLDHJDLRL-UHFFFAOYSA-N triethyl phosphate Chemical compound CCOP(=O)(OCC)OCC DQWPFSLDHJDLRL-UHFFFAOYSA-N 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
- C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
- C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
技术领域
本发明属于医药技术领域,涉及4-吡啶取代酞嗪酮类化合物、其制备方法、药物组合物及用途。
背景技术
全球每年约有75万人死于乙肝及其并发症,包括肝细胞癌、肝硬化、肝功能衰竭等。因此,乙型肝炎病毒感染仍是一种严重危害公众健康的世界性疾病。
目前,干扰素和核苷类抗乙肝病毒药是治疗乙型肝炎病毒感染的两种主要手段。但是干扰素存在耐受性差、不良反应多、费用昂贵等缺点;而目前已上市的6种核苷类药物(拉米夫定、阿德福韦酯、恩替卡恩、替比夫定、替诺福韦和克拉夫定)均作用于乙型肝炎病毒的逆转录酶。由于现有的治疗手段远远不能满足乙肝治疗的临床需求,研究和开发更多作用于新靶点、新机制及全新结构母核的非核苷类小分子抗乙型肝炎病毒药物日益迫切,是目前药物化学领域研究的热点,且具有十分重要的理论、经济和社会意义。
为此,本发明提供一种结构新颖的、可口服的非核苷类小分子HBV病毒抑制剂。
发明内容
申请号为201810905518.8的中国专利申请中的化合物是一类高效、低毒的新型非核苷类抗HBV小分子候选化合物(该专利申请中全部内容被引入本申请中)。不过,该化合物生物利用度和成药性有待于进一步改进。
为此,本发明提供一种如式I所示的4-吡啶取代酞嗪酮类化合物,该类化合物具有改善的药物理化性质和体内药代动力学性质,口服生物利用度高,成药性好,是一类结构新颖的、可口服的非核苷类小分子HBV病毒抑制剂。
鉴于此,本发明提供一种式I化合物或其药学上可接受的盐:
其中,
RA选自卤素或氰基;
RB选自卤素;
RC选自H、烷基、环烷基;
L为连接基团,选自亚烷基、亚烷基的任意碳原子被选自-O-、-CO-中至少一种基团置换所得的基团、亚环烷基;
其中,
R1为H,烷基,芳基,被选自羟基、巯基、烷硫基、氨基烷酰基、羧基、氨基、胍基、脲基、芳基、羟基芳基、杂芳基的基团取代的烷基;
R2为氢或烷基;
R3为氢、叔丁氧羰基;
W选自烷基、卤代烷基、环烷基、杂环基、杂链烃基、芳基、杂芳基、烷氧基、氨基;其中,所述烷基、环烷基、杂环基、杂链烃基、芳基、烷氧基、氨基任选各自独立地被1、2、3或4个选自烷基、羧基、烷氧基、杂环基、芳基、杂芳基的基团取代;
X为单键或亚烷基;
R5,R6各自独立地选自-OH、芳氧基、烷基的任意碳原子被选自-O-、-CO-、-S-中至少一种基团置换所得的基团、氨基酸残基,此处所述氨基酸残基是指氨基酸的α-氨基除去一个氢所得到的基团,所述氨基酸残基中羧基中的羟基任选被烷氧基、芳氧基、杂芳氧基或苄氧基的基团置换;此处所述氨基酸选自L构型、D构型、或L和D混合构型的下列氨基酸:甘氨酸、脯氨酸、丙氨酸、缬氨酸、正缬氨酸、亮氨酸、异亮氨酸、正亮氨酸、2-叔丁基甘氨酸、2-苯基甘氨酸、苯基丙氨酸、酪氨酸、色氨酸、组氨酸、丝氨酸、高丝氨酸、苏氨酸、半胱氨酸、S-甲基半胱氨酸、高半胱氨酸、蛋氨酸、天冬酰胺、谷氨酰胺、天冬氨酸、谷氨酸、赖氨酸、羟基赖氨酸、鸟氨酸、2,4-二氨基丁酸、2,3-二氨基丙酸、精氨酸、瓜氨酸;或者R5、R6与P一起形成杂环基,所述杂环基任选被卤代芳基取代,所述杂环基任选与芳基稠合。
可选地,所述“卤素”选自F、Cl、Br或I;
可选地,所述“烷基”、“卤代烷基”、“烷氧基”、“烷硫基”等任意基团中所具有的烷基各自独立地为C1-C20直链或支链烷基,可选地为C1-C15直链或支链烷基,可选地为C1-C10直链或支链烷基,可选地为C1-C7直链或支链烷基,可选地为C1-C6直链或支链烷基,可选地为C1-C5直链或支链烷基,可选地为C1-C4直链或支链烷基,可选地,选自甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、仲丁基、正戊基,1-甲基丁基、2-甲基丁基、3-甲基丁基、异戊基、1-乙基丙基、新戊基、正己基、1-甲基戊基、2-甲基戊基、3-甲基戊基、异己基、1,1-二甲基丁基、2,2-二甲基丁基、3,3-二甲基丁基、1,2-二甲基丁基、1,3-二甲基丁基、2,3-二甲基丁基、2-乙基丁基、正庚基、2-甲基己基、3-甲基己基、2,2-二甲基戊基、3,3-二甲基戊基、2,3-二甲基戊基、2,4-二甲基戊基、3-乙基戊基或2,2,3-三甲基丁基;可选地,选自甲基、乙基、丙基、异丙基、丁基或异丁基。
可选地,所述“亚烷基”、“亚杂环基烷基”、“氨基烷酰基”等任意基团中所具有的亚烷基各自独立地选自C1-C20直链或支链亚烷基,可选地为C1-C15直链或支链亚烷基,可选地为C1-C10直链或支链亚烷基,可选地为C1-C8直链或支链亚烷基,可选地为C1-C6直链或支链亚烷基,可选地为C1-C4直链或支链亚烷基,可选地为C2-C6直链或支链亚烷基,可选地为C3-C6直链或支链亚烷基;
可选地,所述“杂链烃基”为链上含1个、2个、3个或4个选自N、O、S的杂原子的直链或支链饱和或不饱和C1-C20杂链烃结构,可选地,为链上含1个、2个、3个或4个N的直链或支链饱和或不饱和C1-C20杂链烃结构,可选地,为链上含1个、2个、3个或4个N的直链或支链饱和或不饱和C1-C10杂链烃结构;
可选地,所述“环烷基”为C3-C10单环或双环环烷基,可选地,为C3-C7单环环烷基,可选地,为环丙基、环丁基、环戊基、环已基或环庚基;
可选地,所述“亚环烷基”为C3-C10单环或双环亚环烷基,可选地,为C3-C8单环亚环烷基,可选地,为亚环丙基、亚环丁基、亚环戊基、亚环己基、亚环庚基及亚环辛基。
可选地,所述“亚杂环基”、“杂环基”、“亚杂环基烷基”等任意基团中所具有的杂环为环上含有1个、2个或3个选自N、O、S的杂原子的3-10元非芳香杂环,可选地,所述杂环为环上含有1个或2个选自N、O的杂原子的3-10元非芳香环;所述杂环为环上含有1个或2个选自N、O的杂原子的3-6元非芳香环;可选地,所述杂环为环上含有1个或2个选自N、S的杂原子的3-10元非芳香环;所述杂环为环上含有1个或2个选自N、S的杂原子的3-6元非芳香环;
可选地,所述“芳基”、“羟基芳基”、“卤代芳基”、“芳氧基”等任意基团中所具有的芳基为6-10元芳基;可选为苯基或萘基,可选为苯基、1-萘基、2-萘基;
可选地,所述“杂芳氧基”、“杂芳基”等、“芳氧基”中任意基团中所含的杂芳基的环为含有1-3个选自N、O和S中的杂原子的5-10元杂芳环;可选地,为含有1-2个选自N、O和S中的杂原子的5-10元杂芳环;可选地,所述杂芳环选自吡啶环、吡咯环、嘧啶环、吡嗪环、哒嗪环、噻吩环、呋喃环;可选地,所述杂芳基为选自吡啶-2-基、吡啶-3-基、吡啶-4-基、哒嗪-3-基、哒嗪-4-基、嘧啶-2-基、嘧啶-4-基、嘧啶-5-基、吡嗪-2-基、吡嗪-3-基、吲哚基、异吲哚基、吲唑基、吲嗪基、嘌呤基、喹嗪基、喹啉基、异喹啉基、噌啉基、酞嗪基、萘啶基、喹唑啉基、喹喔啉基、噻吩并[2,3-b]呋喃基、呋喃并[3,2-b]-吡喃基、吡啶并[2,3-d]噁嗪基、吡唑并[4,3-d]噁唑基、咪唑并[4,5-d]噻唑基、吡嗪并[2,3-d]哒嗪基、咪唑并[2,1-b]噻唑基、咪唑并[1,2-b][l,2,4]三嗪基、苯并噻吩基、苯并噁唑基、苯并咪唑基、苯并噻唑基、苯并噁庚因基、苯并噁嗪基、苯并呋喃基、苯并三唑基、吡咯并[2,3-b]吡啶基、吡咯并[3,2-c]吡啶基、吡咯并[3,2-b]吡啶基、咪唑并[4,5-b]吡啶基、咪唑并[4,5-c]吡啶基、吡唑并[4,3-d]吡啶基、吡唑并[4,3-c]吡啶基、吡唑并[3,4-c]吡啶基、吡唑并[3,4-d]吡啶基、吡唑并[3,4-b]吡啶基、咪唑并[1,2-a]吡啶基、吡唑并[1,5-a]吡啶基、吡咯并[1,2-b]哒嗪基、咪唑并[1,2-c]嘧啶基、吡啶并[3,2-d]嘧啶基、吡啶并[4,3-d]嘧啶基、吡啶并[3,4-d]嘧啶基、吡啶并[2,3-d]嘧啶基、吡啶并[2,3-b]吡嗪基、吡啶并[3,4-b]吡嗪基、嘧啶并[5,4-d]嘧啶基、吡唑并[2,3-b]吡嗪基、嘧啶并[4,5-d]嘧啶基,可选为吡啶-2-基、吡啶-3-基、吡啶-4-基、嘧啶-2-基、嘧啶-4-基或嘧啶-5-基;
除非另有说明,所述“烷基”、“亚烷基”、“亚烷基的任意碳原子被选自-O-、-CO-中至少一种基团置换所得的基团”、“芳基”、“杂芳基”或“苄基”各自独立地被选自下列基团的取代基取代:烷基(如甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基)、烯基(如乙烯基、丙烯基)、炔基(如乙炔基、丙炔基)、羟基、烷氧基(如甲氧基、乙氧基、正丙氧基、异丙氧基、叔丁氧基)、酰氧基(如甲酰氧基、乙酰氧基、丙酰氧基、丁酰氧基、异丙基羰基氧基、叔丁基羰基氧基)、硫基、烷硫基(如甲硫基、乙硫基、正丙硫基、异丙硫基、叔丁硫基)、氨基、烷氨基(如甲氨基、乙氨基、二甲氨基、二乙氨基、正丙氨基、异丙氨基、叔丁氨基)、酰氨基(如甲酰氨基、乙酰氨基、丙酰氨基、丁酰氨基、异丙基羰基氨基、叔丁基羰基氨基)、卤素(如氟、氯、溴、碘)、氰基、硝基、酰基(如甲酰基、乙酰基、羧基、甲氧碳基、乙氧羰基、异丙氧羰基、叔丁氧羰基、氨基羰基、N,N-二甲基氨基羰基);可选为甲基、乙基、羟基、甲氧基、乙氧基、乙酰氧基、氨基、二甲氨基、乙酰氨基、氟、氯、氰基、乙酰基、甲氧羰基、乙氧羰基、氨基羰基或N,N-二甲基氨基羰基;
可选地,
RA选自氯、氰基;
RB选自氯;
RC选自H、甲基、环丙基;
其中,此处所述氨基酸残基是指氨基酸中的羧基除去羟基所得的基团,所述氨基酸残基为选自L构型、D构型、或L和D混合构型的下述氨基酸的残基:甘氨酸、脯氨酸、丙氨酸、缬氨酸、正缬氨酸、亮氨酸、异亮氨酸、正亮氨酸、2-叔丁基甘氨酸、2-苯基甘氨酸、苯丙氨酸、酪氨酸、苯乙氨酸、色氨酸、组氨酸、丝氨酸、高丝氨酸、苏氨酸、半胱氨酸、S-甲基半胱氨酸、高半胱氨酸、蛋氨酸、天冬酰胺、谷氨酰胺、天冬氨酸、谷氨酸、赖氨酸、羟基赖氨酸、鸟氨酸、2,4-二氨基丁酸、2,3-二氨基丙酸、精氨酸、瓜氨酸;所述氨基酸中α氨基上的氢原子任选被选自叔丁氧羰基的基团置换,所述氨基酸中α碳上的氢原子任选被烷基置换;
W选自C1-6烷基、羧基C1-6烷基、C5-10杂环基C1-6烷基、C1-6烷氧基C6-10芳基、C1-6烷氧基、一个或两个C1-6烷基取代的氨基、C5-10杂环基;
X为单键、-CH2-、或-CH2(CH3)-;
R5,R6各自独立地选自-OH、C6-10芳氧基、C1-6烷基-O(C=O)O-C1-6亚烷氧基、C1-6烷基(C=O)O-C1-6亚烷氧基、C1-16烷基-O-C1-6亚烷氧基、氨基酸残基,此处所述氨基酸残基是指氨基酸的α-氨基除去一个氢所得到的基团,所述氨基酸残基中羧基中的羟基任选被C1-6烷氧基置换;此处所述氨基酸选自L构型、D构型、或L和D混合构型的下列氨基酸:丙氨酸、缬氨酸、正缬氨酸、亮氨酸、异亮氨酸、正亮氨酸、2-叔丁基甘氨酸、2-苯基甘氨酸、苯基丙氨酸、酪氨酸、色氨酸、组氨酸、丝氨酸、高丝氨酸、苏氨酸、半胱氨酸、S-甲基半胱氨酸、高半胱氨酸、蛋氨酸、天冬酰胺、谷氨酰胺、天冬氨酸、谷氨酸、赖氨酸、羟基赖氨酸、鸟氨酸、2,4-二氨基丁酸、2,3-二氨基丙酸、精氨酸、瓜氨酸,优选丙氨酸;
或者R5、R6与P一起形成C5-10杂环基,所述C5-10杂环基任选被卤代苯基取代,所述C5-10杂环基任选与苯基稠合;
可选地,上述式I化合物或其药学上可接受的盐中,其中所述式I化合物选自下列化合物:
可选地,所述药学上可接受的盐包括式I化合物的阴离子盐和阳离子盐。
可选地,所述药学上可接受的盐包括式I化合物的碱金属的盐、碱土金属的盐、铵盐;可选地,所述碱金属包括钠、钾、锂、铯,所述碱土金属包括镁、钙、锶。
可选地,所述药学上可接受的盐包括式I化合物与有机碱形成的盐;可选地,所述有机碱包括三烷基胺、吡啶、喹啉、哌啶、咪唑、甲基吡啶、二甲氨基吡啶、二甲基苯胺、N-烷基吗啉、1,5-二氮杂双环[4.3.0]壬烯-5、1,8-二氮杂双环[5.4.0]十一碳烯-7、1,4-二氮杂双环[2.2.2]辛烷;可选地,所述三烷基胺包括三甲胺、三乙胺、N-乙基二异丙胺;可选地,所述N-烷基吗啉包括N-甲基吗啉。
可选地,所述药学上可接受的盐包括式I化合物与酸形成的盐;可选地,所述酸包括无机酸、有机酸;可选地,所述无机酸包括盐酸、氢溴酸、氢碘酸、硫酸、硝酸、磷酸、碳酸;可选地,所述有机酸包括甲酸、乙酸、丙酸、草酸、丙二酸、琥珀酸、富马酸、马来酸、乳酸、苹果酸、柠檬酸、枸橼酸、酒石酸、碳酸、苦味酸、甲磺酸、乙磺酸、对甲苯磺酸、谷氨酸、双羟萘酸。
根据本发明的另一方面,还提供了上述式I化合物或其药学上可接受的盐的制备方法,该方法可通过以下反应路线1实现:
该反应路线包括:将Hu1化合物与RDOH进行缩合成酯反应,得到式I化合物,其中,式Hu1和式I中,RA、RB、L的定义如权利要求1-5任一项所述,RC为H;式I中,RD定义如权利要求1-5任一项所述;
或者,该方法通过以下反应路线2实现:
该反应路线包括:将Hu1-1化合物与RDOH进行缩合成酯反应,得到式Hu1-2化合物,其Hu1-2化合物中的RD为权利要求1-5任一项所定义的含有保护基的基团,然后将式Hu1-2化合物与卤化物反应引入RC,任选地脱去RD中的保护基团,得到式I化合物,其中,式Hu1-1、式Hu1-2和式I中,RA、RB、L的定义如权利要求1-5任一项所述;式I中,RD的定义如权利要求1-5任一项所述;式I中,RC为权利要求1-5任一项所定义的不为氢的基团;
任选地,上述反应路线1和反应路线2中,采用保护基团对式Hu1化合物、式Hu1-1、式RDOH化合物进行保护,进行缩合成酯反应后,任选地进行脱保护;
这些保护基的脱去根据常规方法,优选通过在惰性溶剂例如1,4-二氧六环、二氯甲烷中与强酸例如盐酸、氢溴酸或三氟乙酸进行反应实施。
RDOH为式HOOCC(R1)(R2)NHR3、式WCOOH、式PG-(P=O)R5R6化合物,其中R1、R2、R3、W定义如上所述;PG为保护基团,PG优选为五氟苯氧基;R5,R6各自独立地选自-OH、芳氧基、氨基酸残基,此处所述氨基酸残基是指氨基酸的α-氨基除去一个氢所得到的基团,所述氨基酸残基中羧基中的羟基任选被烷氧基、芳氧基、杂芳氧基或苄氧基的基团置换;此处所述氨基酸选自L构型、D构型、或L和D混合构型的下列氨基酸:甘氨酸、脯氨酸、丙氨酸、缬氨酸、正缬氨酸、亮氨酸、异亮氨酸、正亮氨酸、2-叔丁基甘氨酸、2-苯基甘氨酸、苯基丙氨酸、酪氨酸、色氨酸、组氨酸、丝氨酸、高丝氨酸、苏氨酸、半胱氨酸、S-甲基半胱氨酸、高半胱氨酸、蛋氨酸、天冬酰胺、谷氨酰胺、天冬氨酸、谷氨酸、赖氨酸、羟基赖氨酸、鸟氨酸、2,4-二氨基丁酸、2,3-二氨基丙酸、精氨酸、瓜氨酸;或者R5、R6与P一起形成杂环基,所述杂环基任选被卤代芳基取代,所述杂环基任选与芳基稠合。
可选地,上述制备方法中的所述缩合成酯反应中,合适的缩合剂选自碳二亚胺例如N,N’-二环己基碳二亚胺(DCC)或N-(3-二甲基氨基异丙基)-N’-乙基碳二亚胺盐酸盐(EDC)。
缩合成酯反应优选在碱的存在下进行。作为碱,优选使用碱金属碳酸盐,例如碳酸钠或碳酸钾,或有机碱例如三乙胺,N-甲基吗啉,N-甲基哌啶,N,N-二异丙基乙胺或4-N,N-二甲基氨基吡啶。
可选地,所述缩合成酯反应的温度为0℃至+60℃,优选+20℃至+40℃。所述反应优选在常压进行。
或者,上述式I化合物或其药学上可接受的盐还可以采用以下方法制备:
将式Hu1化合物与式Hu2化合物反应,得到式Hu3化合物,再引入R5和R6基团,得到式I化合物。
式I中,RA、RB、RC、L如上所述;RD为其中,X如上所述,R5,R6各自独立地选自-OH、芳氧基、烷基的任意碳原子被选自-O-、-CO-、-S-中至少一种基团置换所得的基团、氨基酸残基,此处所述氨基酸残基是指氨基酸的α-氨基除去一个氢所得到的基团,所述氨基酸残基中羧基中的羟基任选被烷氧基、芳氧基、杂芳氧基或苄氧基的基团置换;此处所述氨基酸选自L构型、D构型、或L和D混合构型的下列氨基酸:甘氨酸、脯氨酸、丙氨酸、缬氨酸、正缬氨酸、亮氨酸、异亮氨酸、正亮氨酸、2-叔丁基甘氨酸、2-苯基甘氨酸、苯基丙氨酸、酪氨酸、色氨酸、组氨酸、丝氨酸、高丝氨酸、苏氨酸、半胱氨酸、S-甲基半胱氨酸、高半胱氨酸、蛋氨酸、天冬酰胺、谷氨酰胺、天冬氨酸、谷氨酸、赖氨酸、羟基赖氨酸、鸟氨酸、2,4-二氨基丁酸、2,3-二氨基丙酸、精氨酸、瓜氨酸;
式Hu2中,X如上所述,Q1、Q2各自独立地为H、烷基;
式Hu3中,RA、RB、RC、L、X如上所述;
R5和R6基团的引入方法包括,将式Hu3化合物与相应的氨基酸进行磷酰胺化反应制得相应的磷酰胺式I化合物,或者与相应的卤代物或醇进行反应制得磷酸酯式I化合物。
Hu3化合物与相应的氨基酸进行胺酸缩合成磷酰胺反应,合适的缩合剂选自碳二亚胺例如N,N’-二环己基碳二亚胺(DCC)或N-(3-二甲基氨基异丙基)-N’-乙基碳二亚胺盐酸盐(EDC)。缩合成酰胺反应优选在碱的存在下进行。作为碱,优选使用碱金属碳酸盐,例如碳酸钠或碳酸钾,或有机碱例如三乙胺,N-甲基吗啉,N-甲基哌啶,N,N-二异丙基乙胺或4-N,N-二甲基氨基吡啶。
Hu3化合物与相应的醇进行醇酸缩合成磷酸酯反应,合适的缩合剂选自碳二亚胺例如N,N’-二环己基碳二亚胺(DCC)或N-(3-二甲基氨基异丙基)-N’-乙基碳二亚胺盐酸盐(EDC)。缩合成磷酸酯反应优选在碱的存在下进行。作为碱,优选使用碱金属碳酸盐,例如碳酸钠或碳酸钾,或有机碱例如三乙胺,N-甲基吗啉,N-甲基哌啶,N,N-二异丙基乙胺或4-N,N-二甲基氨基吡啶。
Hu3化合物与相应的氯代物在碱性条件下进行亲核取代成磷酸酯反应,作为碱,优选氢化钠,氢化钾。
关于保护基团:当多官能团有机化合物进行反应时,为使反应只发生在所希望的官能团处,而避免其他官能团遭受影响,在反应前将其他官能团先加以保护,当反应完成后再恢复。保护基团是这种能够对所述其他官能团提供保护的一类基团的总称。所述氨基的保护基团可以为叔丁氧基碳基(Boc)。羟基或羧基官能团的保护基优选使用叔丁基、乙基、甲基。这些保护基的脱去根据常规方法,优选通过在惰性溶剂例如1,4-二氧六环、二氯甲烷中与强酸例如盐酸、氢溴酸或三氟乙酸进行反应实施。
式Hu1化合物可以按照文献常规方法制备(例如可参照申请号为201810905518.8的专利申请中的制备方法制备)。
可选地,上述式I化合物的药学上可接受的盐,可以通过将式I化合物溶于相应的酸饱和的醇溶液中进行反应而制备,例如:将式I所示的化合物溶于氯化氢饱和的甲醇溶液,室温搅拌30分钟,将溶剂蒸干,即制得相应的式I化合物的盐酸盐。
另一发面,还提供一种药物组合物,其包含治疗有效量的上述式I化合物或其药学上可接受的盐中的一种或多种以及任选存在的药学上可接受的载体。
上述药学上可接受的载体是指药学领域常规的药物载体,例如:稀释剂,如水等;填充剂,如淀粉、蔗糖等;粘合剂,如纤维素衍生物、藻酸盐、明胶、聚乙烯吡咯烷酮;湿润剂,如甘油;崩解剂,如琼脂、碳酸钙和碳酸氢钠;吸收促进剂,如季铵化合物;表面活性剂,如十六烷醇;吸附载体,如高岭土和皂粘土;润滑剂,如滑石粉、硬脂酸钙和硬脂酸镁、和聚乙二醇等。另外,还可以在上述药物组合物中加入其它辅剂,如香味剂和甜味剂等。
上述的式I化合物或其药学上可接受的盐,或药物组合物可以通过口服、直肠或肠外给药的方式施用于需要这种治疗的患者。用于口服时,可以将其制成常规的固体制剂,如片剂、粉剂、粒剂、胶囊等,或制成液体制剂,如水或油悬浮剂,或其它液体制剂,如糖浆等;用于肠外给药时,可将其制成注射用的溶液、水或油性悬浮剂等。
本发明还提供上述的式I化合物或其药学上可接受的盐,或者上述的药物组合物在制备预防和/或治疗乙型肝炎疾病的药物中的用途。
本发明还提供上述的式I化合物或其药学上可接受的盐,或者上述的药物组合物在制备乙型肝炎病毒抑制剂中的用途。
本发明还提供上述的式I化合物或其药学上可接受的盐,或者上述的药物组合物在制备抑制病毒复制的药物中的用途,所述病毒包括甲肝病毒、乙肝病毒、丙肝病毒、流感病毒、腺病毒、艾滋病毒、疱疹病毒、人乳头瘤病毒。
本发明还提供一种预防和/或治疗乙型肝炎疾病的方法,包括给需要的患者施用有效量的上述式I化合物或其药学上可接受的盐,或者上述的药物组合物。
本发明还提供一种抑制乙型肝炎病毒的方法,包括给需要的患者施用有效量的上述式I化合物或其药学上可接受的盐,或者上述的药物组合物。
本发明还提供一种抑制病毒复制的方法,包括给宿主施用有效量的上述式I化合物或其药学上可接受的盐,或者上述的药物组合物。所述病毒包括甲肝病毒、乙肝病毒、丙肝病毒、流感病毒、腺病毒、艾滋病毒、疱疹病毒、人乳头瘤病毒。
根据一方面的具体实施方式,化合物在细胞水平上具有高效的抑制HBV DNA复制的活性,对HepG2.2.15细胞的生长毒性较小。
根据一方面的具体实施方式,化合物具有较好的肝脏靶向性,能在肝脏稳定存在并富集,是有效的乙型肝炎病毒抑制剂。
附图说明
图1显示的是测试实施例3中AAV小鼠外周血中病毒HBV DNA含量随时间变化示意图。
图2显示的是测试实施例3中AAV小鼠外周血中病毒HBsAg含量随时间变化示意图。
图3显示的是测试实施例3中AAV小鼠外周血中病毒HBeAg含量随时间变化示意图。
图4显示的是测试实施例3中给药4周后AAV小鼠肝脏中病毒HBcAg含量示意图;图中,核心蛋白阳性的细胞呈现深黑色,阴性细胞呈现浅黑色。
具体实施方式
以下对本发明的具体实施方式进行详细的说明。应当理解的是,此处所描述的具体实施方式仅用于示例性地对本发明进行说明,并不用于限制本发明。
在以下实施例中,核磁共振氢谱用BrukerAMX-400型、Gemini-300型或AMX–600型核磁共振仪记录,化学位移δ的单位为ppm。比旋光度由Perkin-Elmer241型自动旋光仪测定,所用微波为CEM-discovery微波反应器。如无特别说明,所有反应溶剂均按照常规方法进行纯化。柱层析用硅胶(200-300目)为青岛海洋化工分厂生产。薄层层析使用GF254高效板,为烟台化工研究所生产。制备型薄层层析板由中国科学院上海药物研究所制备,固定相采用GF254(HG/T2354-92)硅胶和羧甲基纤维素钠(800-1200)制备,分别为青岛海洋化工有限公司和中国医药(集团)上海化学试剂公司生产。如无特别标注,所有溶剂均为分析纯试剂,所用试剂均购自国药集团化学试剂有限公司。采用碘、紫外荧光等方法显色。减压蒸除有机溶剂在旋转蒸发仪中进行。
实施例1:化合物1的合成路线如下:
步骤(i):
将3,6-二氯酞嗪i-1(10g,50.3mmol)加入到醋酸(150mL)中,120℃回流6小时,TLC监测反应完全后,停止反应并将反应液冷却至室温,减压旋蒸除去醋酸得到白色固体化合物i-2。
步骤(ii):
将化合物i-2(1.0g,5.5mmol)溶于DMF(70mL)中,依次加入4-氰基苄氯(1.26g,6.6mmol)和Cs2CO3(2.1g,6.6mmol)。反应体系在50℃下搅拌5小时后,TLC监测反应完全。向反应溶液中加入乙酸乙酯(100mL)和水(100mL),分出有机层,有机层依次用水(100mL x 4)和饱和食盐水(100mL)洗涤。有机相用无水硫酸钠干燥半个小时后过滤浓缩得粗产物,该粗产物用柱层析(PE:EA=100:0~10:1)分离纯化得白色固体化合物i-3。
步骤(iii):
将化合物i-3(97mg,0.33mmol)溶于1,4-二氧六环(20mL)和水(5mL)的混合溶剂中,依次加入2,6-二氟-吡啶-3-硼酸(68.3mg,0.43mmol)、Pd(PPh3)4(76.0mg,0.033mmol)和K3PO4(139mg,0.66mmol)。N2置换3次后100℃反应过夜。次日TLC监测反应完全,将反应体系冷却至室温。减压旋蒸除去溶剂后,将残余物用乙酸乙酯萃取(30mL)溶解,有机层依次用水(30mL x 3)和饱和食盐水(30mL)洗涤,无水硫酸钠干燥、过滤、浓缩得粗产物,该粗产物用柱层析(PE:EA=67:33)分离纯化得化合物i-4。
步骤(iv):
将化合物i-4(150mg,0.4mmol)溶于无水乙醇(10mL)中,加入3-氨基-1-丙醇(4mmol),回流反应过夜。次日旋转蒸干溶剂,残余物溶于乙酸乙酯(50mL)和水(50mL),有机层用饱和食盐水(30mL)洗涤,无水硫酸钠干燥、过滤、浓缩得粗产物,该粗产物用柱层析(PE:EA=50:50)分离纯化得白色固体化合物i-5。
步骤(v):
将化合物i-5(0.19mmol)溶于无水乙腈(10mL)中,加入N-氯代丁二酰亚胺(25mg,0.19mmol),回流5小时。旋干溶剂得粗产物,粗产物用柱层析(PE:EA=60:40)分离纯化得白色固体化合物1(收率81%)。1H NMR(400MHz,Chloroform-d)δ8.53–8.46(m,1H),7.85–7.78(m,2H),7.68–7.51(m,6H),5.87(t,J=5.9Hz,1H),5.48(s,2H),3.80(t,J=5.6Hz,2H),3.69(q,J=6.1Hz,2H),1.96–1.85(m,2H).
化合物I-1的合成路线如下所示:
步骤a:
Boc-L-缬氨酸(1.85g,8.5mmol)、二环已基碳二亚胺(1.4g,6.8mmol)以及4-二甲氨基吡啶(0.34g,2.8mmol),分别加到化合物1(2.63g 5.67mmol)的二氯甲烷(50ml)溶液中,加完后继续室温反应1小时。反应结束后,抽滤,减压蒸去滤液中的二氯甲烷,残余物用乙酸乙酯溶解,依次用水、饱和食盐水洗涤,收集乙酸乙酯层,无水硫酸钠干燥,滤液蒸干,得粗产物,粗品用硅胶柱层析(PE/EA 75/25)纯化,得白色固体I-1(3.4g,92%)。
步骤b:
将I-1(3.4g 5.6mmol)溶于25mL二氯甲烷中,加入5mL三氟乙酸,油浴温度40℃反应3h,加入饱和碳酸氢钠溶液调节pH值至中性,二氯甲烷萃取3次,无水硫酸钠干燥,过滤,旋干溶剂,粗品经硅胶柱层析(二氯甲烷/甲醇94/6)得白色固体I-2(2.7g,94%)。
实施例2:
步骤a:
化合物I-1(85mg,0.13mmol)溶于干燥的四氢呋喃(5mL)中,0℃下,滴加到60%NaH(25mg,64mmol)中,搅拌30分钟。加入碘甲烷(9.58uL,0.15mmol)的四氢呋喃(2mL)溶液,加毕,反应液逐渐升至室温搅拌过夜,反应液倒入冰水中,乙酸乙酯(20mL×3)萃取,有机相无水硫酸钠干燥,过滤,减压蒸除溶剂,残余物经硅胶柱层析,得白色粉末状固体化合物I-33’(47mg,55%)。
步骤b:
将I-33’(40mg 0.059mmol)溶于5mL二氯甲烷中,加入0.5mL三氟乙酸,油浴温度40℃反应3h,加入饱和碳酸氢钠溶液调节pH值至中性,二氯甲烷萃取3次,无水硫酸钠干燥,过滤,旋干溶剂,粗品经硅胶柱层析(二氯甲烷/甲醇95/5)得白色固体I-34(32mg,94%)。
实施例3:
步骤:将化合物1(300mg,0.65mmol)溶解于四氢呋喃中,氮气保护、-5℃条件下,依次加入叔丁基溴化镁的四氢呋喃(1.35mmol,1.35mL,c 1mol/L)溶液,N-[(S)-(2,3,4,5,6-五氟苯氧基)苯氧基磷酰基]-L-丙氨酸异丙酯B(351mg,0.775mmol)的四氢呋喃溶液,反应液逐步升温至5℃,反应17h。TLC监测无原料,加水淬灭反应,旋干溶剂后,加入100mL水,乙酸乙酯萃取3次(50mL*3),饱和食盐水洗涤,无水硫酸钠干燥,过滤,旋干溶剂得粗产物。该粗产物经硅胶柱层析纯化(石油醚/乙酸乙酯90/10-50/50)得白色固体化合物I-36(280mg,52%)。
实施例4:
步骤a:
将化合物1(4.64g,10mmol)溶于50mLDMF中,搅拌下分批加入80%NaH(0.64g,26.7
mmol),室温搅拌15分钟。冰盐浴(-10℃)下滴加对甲苯磺酰氧甲基膦酸二乙酯(0.45g,14mmol),加毕,保持温度在-10~0℃之间搅拌1h,后升至室温搅拌4~5h。滴加冰醋酸调pH至中性(约1mL),过滤,滤饼用二氯甲烷洗涤,合并滤液,有机相用水(30mL×3)洗涤,水相再用二氯甲烷(20mL×3)萃取,合并二氯甲烷相,无水硫酸钠干燥,过滤,减压蒸除溶剂,残余物中加入甲苯,冷冻过夜。过滤,滤饼于50℃减压干燥,得白色粉末状固体化合物2(2.88g,47%)。
步骤b:
在100mL反应瓶中,将化合物2(2.5g,4.07mmol)溶于20mL氢溴酸的水溶液中,升温水解,充分反应后冷却,加入二氯甲烷萃取,有机层干燥,过滤,浓缩,粗品经硅胶柱层析(二氯甲烷/甲醇85/15)分离得到白色固体化合物3(1.68g,74%)。
步骤c:
100mL反应瓶中,分别投入化合物3(557mg,1mmol)、氯甲基碳酸异丙酯(760mg,5mmol)、N-甲基吡咯烷酮(880mg,8.8mmol)和三乙胺(310mg,3mmol),室温搅拌12h,然后升温至50~60℃,搅拌4h。冷却至室温,加入乙酸异丙酯250mL,室温搅拌1~2h。过滤,滤饼用20mL乙酸异丙酯洗涤,滤液用饱和氯化钠水溶液(100mL×3)洗涤,有机层用无水硫酸钠干燥,过滤,滤液减压浓缩得油状物,油状物加入丙酮10mL,搅拌10min,充分搅拌均匀后,加入无水乙醚20mL析晶,此时溶液变浑浊,继续搅拌7~8h。过滤,无水乙醚洗涤,晾干得到白色固体粉末,即为目标化合物I-38(395mg,收率50%)。
实施例5:
步骤a:
将化合物3(0.5g,0.9mmol)、苯酚(84mg,0.9mmol)、二环已基碳二亚胺(0.22g,1.07mmol)以及三乙胺(0.181g,1.8mmol),分别加到N-甲基吡咯烷酮(20mL)溶液中,100℃下反应24小时。反应结束后,加入大量水,二氯甲烷萃取3次,有机相用水洗,无水硫酸钠干燥,抽滤,减压蒸去二氯甲烷,得残余物280mg,直接下一步反应。
步骤b:
残余物(280mg,0.44mmol)溶于20mL乙腈中,加入0.5mL二氯亚砜,75℃反应2小时,将反应液浓缩至干,残留物溶于干燥20mL二氯甲烷中,冷却至-78℃,加入L-丙氨酸异丙酯盐酸盐(61mg,0.44mmol)),三乙胺(0.181g,1.8mmol),反应1.5小时,加入水,二氯甲烷萃取3次,有机相用水洗,收集二氯甲烷层,无水硫酸钠干燥,抽滤,减压蒸去二氯甲烷得粗品,粗品用硅胶柱层析(二氯甲烷/甲醇85/15)纯化,得白色固体化合物I-40(0.13g,41%)。
实施例6:
步骤a:
将化合物3(0.5g,0.9mmol)、草酰氯(0.2mL)、1滴N,N-二甲基甲酰分别加到二氯甲烷(20mL)溶液中,回流反应3小时。将反应液浓缩至干,残留物溶于干燥二氯甲烷(20ml)中,加入L-丙氨酸乙酯盐酸盐(0.344g,2.24mmol)),二异丙基乙基胺(0.46g,3.58mmol),反应1.5小时,加入水,二氯甲烷萃取3次,有机相用水洗,收集二氯甲烷层,无水硫酸钠干燥,抽滤,减压蒸去滤液中的二氯甲烷得粗品,粗品用硅胶柱层析(二氯甲烷/甲醇90/10)纯化,得白色固体化合物I-41(0.31g,45%)。
实施例7:
步骤a:
40℃下,将三氯氧膦(2.3g,15mmol)加入到1(0.464g,1mmol)的磷酸三乙酯(10mL)溶液中,搅拌1h。加入三乙胺/碳酸氢铵缓冲溶液(1M,pH 7),减压浓缩至干,残留物加入二氯甲烷和水,水相用二氯甲烷萃取3次,合并有机相,干燥,过滤,除去溶剂得粗品,粗品溶于少量二氯甲烷,加入大量冷乙醚,析出固体,过滤,乙醚洗涤,得产物化合物4(0.45g83%)。
步骤b:
L-丙氨酸异丙酯(0.106g,0.81mmol)、二环已基碳二亚胺(0.17g,0.81mmol)分别加到化合物4(0.4g 0.735mmol)的叔丁醇-水(1/1 50mL)溶液中,加完后回流反应1小时。反应结束后,减压蒸去溶剂,残余物用二氯甲烷溶解,然后依次用水、饱和食盐水洗,收集二氯甲烷层,无水硫酸钠干燥,滤液蒸干,得粗产物,粗品用硅胶柱层析(二氯甲烷/甲醇85/15)纯化,得白色固体化合物I-42(0.29g,60%)。
实施例8:
将化合物4(0.5g,0.92mmol)、2-(十六烷氧基)乙醇(0.263g,0.92mmol)、二环已基碳二亚胺(0.22g,1.07mmol)以及三乙基胺(0.181g,1.8mmol),分别加到二氯甲烷(20mL)中,室温反应24小时。反应结束后,过滤,滤液加入大量水,二氯甲烷萃取3次,有机相用水洗,收集二氯甲烷层,干燥,抽滤,减压蒸去滤液中的二氯甲烷,得粗产物,粗品用硅胶柱层析(二氯甲烷/甲醇85/15)纯化,得白色固体化合物I-43(0.28g,50%)。
实施例9:
步骤a:
-20℃,氮气保护下,将新蒸的三氯化膦PCl3(0.85mL,1.3g,9.5mmol)滴加到邻羟基苄醇(1.01g,8.10mmol)的乙醚(30mL)溶液中,10分钟后,反应体系中滴加三乙胺(1.89g,2.60mL,18.7mmol)的乙醚溶液(约2-3h),加毕,升温至室温,继续搅拌1h,将反应体系置于-20℃过夜,过滤除去三乙胺的盐酸盐,滤液浓缩得黄色油状物化合物5(1.30g),该粗品化合物5直接用于下一步反应。
步骤b:
氮气保护下,二异丙胺(866mg,1.20mL,8.56mmol)的乙醚(4mL)溶液滴加到化合物5的乙醚溶液(9mL)中,室温搅拌3小时,过滤,滤液减压浓缩得粗品化合物6(1.04g),直接用于下一步反应。
步骤c:
0℃,氮气保护下,将化合物1(172mg,0.37mmol))、吡啶盐酸盐(179mg,1.51mmol)溶于乙腈(10mL)中,将粗品化合物6(241mg)的乙腈(5mL)溶液加入到上述溶液,反应液在0℃下搅拌3小时。体系中加入叔丁基过氧化氢的正癸烷溶液(0.23mL,1.3mmol,C 5.5M),升至室温继续反应1小时,减压蒸除溶剂,残余物经硅胶柱层析(二氯甲烷/甲醇95/5)纯化,得无色泡沫化合物I-44(0.12g,51%)。
实施例10:
准确称取I-2(300mg)于茄形瓶中,加入30mL乙腈溶剂并在60℃条件下不断搅拌,而后在60℃条件下缓慢加入1.2倍当量的盐酸溶液(约55ul浓盐酸溶用10mL乙腈稀释)。将反应相在60℃条件下混悬1小时后,冷却至室温,静置12小时。将析出的固体过滤,用少量乙腈洗涤3次。之后将获得的固体在真空干燥箱干燥得到I-46,浅黄色固体310毫克(97%)。
生物活性检测实施例
测试实施例1:实施例中制得的化合物对乙型肝炎病毒DNA复制能力的影响
1、实验材料
1.1筛选体系
稳定转染全长HBV的人肝癌细胞HepG2.2.15细胞株(中科院上海药物研究所提供)
1.2实验仪器
培养箱(ThermoForma3111);酶标仪(Molecular Devices Spectra Max 190);电子天平;显微镜;生物安全柜(Heal Force safe15);离心机(Eppendorf Centrifuge5810R);Real-Time PCR(FASTA GEN-DNA fast2000)
1.3实验药物和试剂
阳性药及配置:拉米夫定(3TC),由中科院上海药物研究所药物化学组合成,用DMEM/High Glucose培养液(Dulbecco’s modified Eagle’s medium,Hyclone公司)配置成40mM储液待用。
其他溶液及配置:
DMEM/High Glucose培养液:Dulbecco’s modified Eagle’s medium 1×(Hyclone公司)磷酸盐缓冲液(PBS,pH7.3,1L):NaCl,8.0g;Na2HPO4,1.16g;KH2PO4,0.2g;KCl:0.2g;
MTT溶液:MTT(Sigma公司),用PBS配制成5mg/ml;
2、实验方法
2.1细胞培养
HepG2.2.15细胞按常规方法培养传代。利用的培养基为DMEM,内含有10%(v/v)牛血清及选择抗生素G418,在37℃,5%CO2的培养箱中培养8天(第4天换液)。
2.2待测化合物及阳性药的配制
待测化合物用DMSO配置成40mM的储备液,含10%HycloneTM Fetal Bovine Serum的DMEM培养液配成指定最高浓度的溶液并稀释;阳性药为拉米夫定,同样以含10%HycloneTM Fetal Bovine Serum的DMEM培养液配成指定浓度。
2.3 MTT测定细胞毒性
HepG2.2.15细胞以5×103细胞/孔接种于96孔板,按上述方法在药物作用下培养八天,取出上清200μl后加入MTT溶液,培养4h后加入裂解液,培养12h后用酶标仪测定OD570,与对照孔的吸光度进行比较,计算存活细胞百分比,并计算出致半数细胞毒性所需浓度CC50。
2.4细胞培养上清中HBV DNA含量的测定
HepG2.2.15细胞经不同浓度的化合物作用8天(第4天换液)后,吸取培养上清,采用实时PCR(Real-time PCR)法定量检测上清中成熟病毒粒子内含有的HBV DNA。
1)收96孔板上清DNA,200μl每孔,将复孔均收集至同一个EP管中,4000rcf*5min离心,取上清;
3)加入200μl乙醇,涡旋使其完全混匀;
5)将DNeasy Mini spin column置于新的2ml废液收集管,加入500μl Buffer AW1(Qiagen,Blood&Tissue Kit),6000rcf*1min离心,弃去上清;
6)将DNeasy Mini spin column置于新的2ml废液收集管,加入500μl BufferAW2,(Qiagen,Blood&Tissue Kit)20000rcf*3min离心,弃去上清;
7)将DNeasy Mini spin column置于新的1.5ml EP管内,吸取50μl Buffer AE(Qiagen,Blood&Tissue Kit)直接加入DNeasy Mini spin column的膜上,在室温放置5min,6000rcf*1min离心洗脱膜上的DNA,弃去DNeasy Mini spin column,收集DNA样品至-20℃。
实时PCR检测上清HBV DNA(乙型肝炎病毒核酸定量检测试剂盒,达安基因)
1)标准曲线:1e7-1e4 IU/ml,1μl上样,设置一个空白孔,以检测反应体系是否污染;
2)按顺序加DNA样品1μl;
3)加入酶及反应缓冲液:先将两管反应液加入酶中,混匀之后稍微离心置于冰上,在上样后加入酶反应液19μl,加入时确保不触碰到DNA样品造成污染;
4)贴上封膜,离心;
5)PCR反应:
第一阶段:93℃,2min
第二阶段:10个循环
第一步:93℃,45s
第二步:55℃,1min
第三阶段:45个循环
第一步:93℃,30s
第二步:55℃,45s
样品:20μl
检测:在完成第三阶段的第二步(55℃,45s)后收集数据。
2.8数据处理
采用Origin软件对实验数据进行统计,计算IC50
实验结果:实验结果如表1所示。
表1:实施例的式I化合物对HepG2.2.15细胞的毒性和抑制HBV DNA的活性
注:CC50为实施例的化合物对HepG2.2.15细胞的生长的影响,半数(50%)致死浓度。IC50为实施例的化合物对乙肝病毒DNA复制的抑制达半数(50%)时的浓度。
从测试结果可以看出,实施例的化合物的IC50均小于10μM,在细胞水平上都具有高的抑制HBV DNA复制的活性,且对HepG2.2.15细胞的生长毒性较小。
测试实施例2:药代动力学研究
取ICR(CD-1)雄性小鼠(体重:~20g),每组每个时间点动物数为3,分别灌胃给药20mg/kg剂量给予化合物I-2、化合物I-36和对比化合物1,采血时间点安排为口服组0min、15min、30min、1h、2h、4h、8h及24h。采血后离心制备血浆,并按20μL分装,于–70℃保存直至分析。药动学参数用Kinetica 5.0软件(美国)非房室模型分析处理。
通过LC-MS分别测定化合物1和化合物1的活性代谢产物1-M在血浆中的浓度,结果汇总在表2中。
表2:口服实施例化合物I-2、实施例化合物I-36和对比化合物1小鼠药代动力学参数(给药方式:口服20mg/kg)
备注:表中“-”表示未测量到。
表2中化合物1的PK数据表明,在口服化合物1之后的血浆中检测到非常有限的药物相关化合物(包括化合物1和活性代谢产物1-M)。式I-2化合物、式I-36化合物可以在口服后将药物有效地传递到血浆中,所述药物包括化合物1和活性代谢化合物1-M。表2的PK数据表明,本发明式I所示化合物是可以适用于口服的非核苷类小分子HBV病毒抑制药物。
测试实施例3:
取6~8周的Balb/c雄性小鼠(体重:~20g),将重组病毒AAV8-HBV病毒液以1×1011vg/只(Viral genome,vg)的剂量尾静脉注射,构建野生型HBV慢性感染小鼠模型。在感染4周后,将血清中的病毒含量持续稳定的感染小鼠随机分为三组,每组六只,分别为模型组(0.5%CMC-Na溶剂对照组),化合物I-2 100mg/kg剂量组和恩替卡韦(ETV)1mg/kg剂量组(阳性药组)。化合物I-2组每天口服给药两次(Bid),模型组和阳性药组每天口服给药一次(Qd)。连续给药4周,每周眼眶取血,分别用qPCR和免疫荧光法检测外周血中病毒的含量和病毒相关分泌蛋白(HBeAg和HBsAg)含量;完成4周药物治疗后,安乐死小鼠取肝脏,免疫组化检测肝脏中的HBcAg水平。
结果显示口服化合物I-2给药在给药一周后,外周血中的病毒HBV DNA含量(图1)和HBsAg(图2)与HBeAg(图3)水平与模型组相比均有显著性下降(P<0.001,Two-wayANOVA),而恩替卡韦(ETV)治疗只降低外周血中的病毒HBV DNA含量,对HBsAg与HBeAg无抑制作用。
药物治疗4周后用特异性抗HBcAg抗体检测肝脏中的HBcAg水平。免疫组化结果显示,在肝组织切片中,核心蛋白阳性的细胞呈现深黑色,阴性细胞呈现浅黑色,如图4,化合物I-2治疗组小鼠肝脏中呈现核心蛋白阳性的肝细胞明显减少,而ETV给药组与模型组无差异。
上述化合物I-2体内药效学结果表明,化合物I-2不仅可以降低感染动物体内HBVDNA水平,还能减少体内HBcAg、HBsAg和HBeAg抗原水平。而HBsAg和HBeAg作为临床上用来判断乙肝病毒感染状态和功能性治愈的指标,具有重大临床意义。
本发明化合物尤其适用于预防或治疗肝病,所述肝病包括例如肝癌、肝脏感染,包括肝炎感染。
以上详细描述了本发明的优选实施方式,但是,本发明并不限于上述实施方式中的具体细节,在本发明的技术构思范围内,可以对本发明的技术方案进行多种简单变型,这种简单变型均属于本发明的保护范围。
Claims (22)
1.一种式I化合物或其药学上可接受的盐:
其中,
RA选自卤素或氰基;
RB选自卤素;
RC选自H、C1-C6直链或支链烷基、C3-C7单环环烷基;
L为连接基团,选自C1-C6直链或支链亚烷基、C3-C8单环亚环烷基;
其中,
R1为H,C1-C6直链或支链烷基,苯基,被选自羟基、氨基、巯基、C1-C6直链或支链烷硫基、羧基、胍基、苯基、羟基苯基、含有1-3个选自N的杂原子的5-10元杂芳基的基团取代的C1-C6直链或支链烷基;
R2为氢;
R3为氢、叔丁氧羰基;
X为单键或C1-C6直链或支链亚烷基;
R5,R6各自独立地选自-OH、苯氧基、萘基氧基、C1-C6直链或支链烷基的任意碳原子被选自-O-、-CO-中至少一种基团置换所得的基团、丙氨酸残基,此处所述丙氨酸残基是指氨基酸的α-氨基除去一个氢所得到的基团,所述丙氨酸残基中羧基中的羟基任选被C1-C6直链或支链烷氧基基团置换;或者R5、R6与P一起形成含有1个或2个氧杂原子的3-10元非芳香环的杂环基,所述杂环基任选被卤代苯基取代,所述杂环基任选与苯基稠合;
所述“卤素”选自F、Cl、Br或I。
2.根据权利要求1所述的式I化合物或其药学上可接受的盐,所述“C1-C6直链或支链烷基”、“C1-C6直链或支链卤代烷基”、“C1-C6直链或支链烷氧基”、或“C1-C6直链或支链烷硫基”中所具有的烷基各自独立地选自甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、仲丁基、正戊基,1-甲基丁基、2-甲基丁基、3-甲基丁基、异戊基、1-乙基丙基、新戊基、正己基、1-甲基戊基、2-甲基戊基、3-甲基戊基、异己基、1,1-二甲基丁基、2,2-二甲基丁基、3,3-二甲基丁基、1,2-二甲基丁基、1,3-二甲基丁基、2,3-二甲基丁基、2-乙基丁基。
3.根据权利要求1所述的式I化合物或其药学上可接受的盐,各个所述“C1-C6直链或支链亚烷基”各自独立地选自C1-C4直链或支链亚烷基。
4.根据权利要求1所述的式I化合物或其药学上可接受的盐,各个所述“C1-C6直链或支链亚烷基”各自独立地选自C2-C6直链或支链亚烷基。
5.根据权利要求1所述的式I化合物或其药学上可接受的盐,所述C3-C7单环环烷基为环丙基、环丁基、环戊基、环已基或环庚基。
6.根据权利要求1所述的式I化合物或其药学上可接受的盐,所述C3-C8单环亚环烷基为亚环丙基、亚环丁基、亚环戊基、亚环己基、亚环庚基及亚环辛基。
7.根据权利要求1所述的式I化合物或其药学上可接受的盐,所述R1为含有1-3个选自N的杂原子的5-10元杂芳基团取代的C1-C6直链或支链烷基时,其杂芳基选自吡啶环、吡咯环、嘧啶环、吡嗪环、哒嗪环。
8.根据权利要求1所述的式I化合物或其药学上可接受的盐,R1为含有1-3个选自N的杂原子的5-10元杂芳基团取代的C1-C6直链或支链烷基时,其杂芳基选自吡啶-2-基、吡啶-3-基、吡啶-4-基、哒嗪-3-基、哒嗪-4-基、嘧啶-2-基、嘧啶-4-基、嘧啶-5-基、吡嗪-2-基、吡嗪-3-基。
9.根据权利要求1所述的式I化合物或其药学上可接受的盐,R5、R6与P一起可形成含有1个或2个氧杂原子的3-6元非芳香环的杂环基。
10.一种式I化合物或其药学上可接受的盐,
RA选自氯、氰基;
RB选自氯;
RC选自H、甲基、环丙基;
其中,此处所述氨基酸残基是指氨基酸中的羧基除去羟基所得的基团,所述氨基酸残基为选自L构型、D构型、或L和D混合构型的下述氨基酸的残基:甘氨酸、脯氨酸、丙氨酸、缬氨酸、正缬氨酸、亮氨酸、异亮氨酸、正亮氨酸、2-叔丁基甘氨酸、2-苯基甘氨酸、苯丙氨酸、酪氨酸、苯乙氨酸、色氨酸、组氨酸、丝氨酸、高丝氨酸、苏氨酸、半胱氨酸、S-甲基半胱氨酸、高半胱氨酸、蛋氨酸、天冬酰胺、谷氨酰胺、天冬氨酸、谷氨酸、赖氨酸、羟基赖氨酸、鸟氨酸、2,4-二氨基丁酸、2,3-二氨基丙酸、精氨酸、瓜氨酸;所述氨基酸中α氨基上的氢原子任选被选自叔丁氧羰基的基团置换,所述氨基酸中α碳上的氢原子任选被C1-C6直链或支链烷基置换;
X为单键、-CH2-、或-CH2(CH3)-;
R5,R6各自独立地选自-OH、苯氧基、萘基氧基、C1-6直链或支链烷基-O(C=O)O-C1-6直链或支链亚烷氧基、C1-6直链或支链烷基(C=O)O-C1-6直链或支链亚烷氧基、C1-6直链或支链烷基-O-C1-6直链或支链亚烷氧基、丙氨酸残基,此处所述丙氨酸残基是指丙氨酸的α-氨基除去一个氢所得到的基团,所述丙氨酸残基中羧基中的羟基任选被C1-6直链或支链烷氧基置换;
或者R5、R6与P一起形成含有1个或2个氧杂原子的5-10元非芳香环的杂环基,所述杂环基任选被卤代苯基取代,所述C5-10杂环基任选与苯基稠合。
12.根据权利要求1-11任一项所述的式I化合物或其药学上可接受的盐,其特征在于,所述药学上可接受的盐包括式I化合物的阴离子盐和阳离子盐。
13.根据权利要求1-11任一项所述的式I化合物或其药学上可接受的盐,其特征在于,所述药学上可接受的盐包括式I化合物的碱金属的盐、碱土金属的盐、铵盐;所述碱金属包括钠、钾、锂、铯,所述碱土金属包括镁、钙、锶。
14.根据权利要求1-11任一项所述的式I化合物或其药学上可接受的盐,其特征在于,所述药学上可接受的盐包括式I化合物与有机碱形成的盐;
所述有机碱包括三烷基胺、吡啶、喹啉、哌啶、咪唑、甲基吡啶、二甲氨基吡啶、二甲基苯胺、N-烷基吗啉、1,5-二氮杂双环[4.3.0]壬烯-5、1,8-二氮杂双环[5.4.0]十一碳烯-7、1,4-二氮杂双环[2.2.2]辛烷。
15.根据权利要求14所述的式I化合物或其药学上可接受的盐,其特征在于,所述三烷基胺包括三甲胺、三乙胺、N-乙基二异丙胺。
16.根据权利要求14所述的式I化合物或其药学上可接受的盐,其特征在于,所述N-烷基吗啉包括N-甲基吗啉。
17.根据权利要求1-11任一项所述的式I化合物或其药学上可接受的盐,其特征在于,所述药学上可接受的盐包括式I化合物与酸形成的盐;
所述酸包括无机酸、有机酸;所述无机酸包括盐酸、氢溴酸、氢碘酸、硫酸、硝酸、磷酸、碳酸;所述有机酸包括甲酸、乙酸、丙酸、草酸、丙二酸、琥珀酸、富马酸、马来酸、乳酸、苹果酸、柠檬酸、枸橼酸、酒石酸、碳酸、苦味酸、甲磺酸、乙磺酸、对甲苯磺酸、谷氨酸、双羟萘酸。
18.权利要求1-17任一项所述的式I化合物或其药学上可接受的盐的制备方法,该方法通过以下反应路线1实现:
该反应路线包括:将Hu1化合物与RDOH进行缩合成酯反应,得到式I化合物,其中,式Hu1和式I中,RA、RB、L的定义如权利要求1-17任一项所述,RC为H;式I中,RD定义如权利要求1-17任一项所述;
或者,该方法通过以下反应路线2实现:
该反应路线包括:将Hu1-1化合物与RDOH进行缩合成酯反应,得到式Hu1-2化合物,其Hu1-2化合物中的RD为权利要求1-17任一项所定义的含有保护基的基团,然后将式Hu1-2化合物与卤化物反应引入RC,任选地脱去RD中的保护基团,得到式I化合物,其中,式Hu1-1、式Hu1-2和式I中,RA、RB、L的定义如权利要求1-17任一项所述;式I中,RD的定义如权利要求1-17任一项所述;式I中,RC为权利要求1-17任一项所定义的不为氢的基团;
任选地,上述反应路线1和反应路线2中,采用保护基团对式Hu1化合物、式Hu1-1和式RDOH化合物进行保护,进行缩合成酯反应后,任选地进行脱保护;
RDOH为式HOOCC(R1)(R2)NHR3、式PG-(P=O)R5R6化合物,其中R1、R2、R3定义如权利要求1-17任一项所述;PG为五氟苯氧基;R5,R6各自独立地选自-OH、苯氧基、丙氨酸残基,此处所述氨基酸残基是指氨基酸的α-氨基除去一个氢所得到的基团,所述丙氨酸残基中羧基中的羟基任选被C1-C6直链或支链烷氧基的基团置换;或者R5、R6与P一起形成含有1个或2个氧杂原子的3-10元非芳香环的杂环基,所述杂环基任选被卤代苯基取代,所述杂环基任选与苯基稠合;
所述缩合成酯反应中,缩合剂选自N,N’-二环己基碳二亚胺或N-(3-二甲基氨基异丙基)-N’-乙基碳二亚胺盐酸盐;
所述缩合成酯反应在碱的存在下进行;所述碱选自碱金属碳酸盐或有机碱,所述碱金属碳酸盐选自碳酸钠、碳酸钾,所述有机碱选自三乙胺、N-甲基吗啉、N-甲基哌啶、N,N-二异丙基乙胺、4-N,N-二甲基氨基吡啶;
所述缩合成酯反应的温度为0℃至+60℃;
所述缩合成酯反应在常压进行;
或者,权利要求1-17任一项所述式I化合物或其药学上可接受的盐采用以下方法制备:
将式Hu1化合物与式Hu2化合物反应,得到式Hu3化合物,再引入R5和R6基团,得到式I化合物;
式I中,
RA、RB、RC、L如权利要求1-17任一项所述;RD为其中,X如权利要求1-17任一项所述,R5,R6各自独立地选自-OH、苯氧基、C1-C6直链或支链烷基的任意碳原子被选自-O-、-CO-中至少一种基团置换所得的基团、丙氨酸残基,此处所述丙氨酸残基是指氨基酸的α-氨基除去一个氢所得到的基团,所述丙氨酸残基中羧基中的羟基任选被C1-C6直链或支链烷氧基基团置换;
式Hu2中,X如权利要求1-17任一项所述,Q1、Q2各自独立地为H、烷基;
式Hu3中,RA、RB、RC、L、X如权利要求1-17任一项所述;
R5和R6基团的引入方法包括,将式Hu3化合物与相应的氨基酸进行磷酰胺化反应制得相应的磷酰胺式I化合物,或者与相应的卤代物或醇进行反应制得磷酸酯式I化合物;
所述式I化合物的药学上可接受的盐,通过将式I化合物溶于相应的酸饱和的醇溶液中进行反应而制备。
19.一种药物组合物,其包含治疗有效量的权利要求1-17任一项所述式I化合物或其药学上可接受的盐中的一种或多种以及任选存在的药学上可接受的载体。
20.根据权利要求19所述的药物组合物,其特征在于,所述药物组合物的剂型包括口服制剂、直肠给药制剂、肠外给药制剂;
所述口服制剂包括固体制剂、液体制剂,
所述固体制剂包括片剂、粉剂、粒剂、胶囊;
所述液体制剂包括水或油悬浮剂、糖浆;
所述肠外给药制剂包括注射用的溶液、水或油性悬浮剂。
21.权利要求1-17任一项所述的式I化合物或其药学上可接受的盐,或者权利要求19或20所述的药物组合物在制备预防和/或治疗乙型肝炎疾病的药物中的用途。
22.权利要求1-17任一项所述的式I化合物或其药学上可接受的盐,或者权利要求19或20所述的药物组合物在制备乙型肝炎病毒抑制剂中的用途。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2019105559217 | 2019-06-25 | ||
CN201910555921 | 2019-06-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112125881A CN112125881A (zh) | 2020-12-25 |
CN112125881B true CN112125881B (zh) | 2023-03-28 |
Family
ID=73851144
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010600646.9A Active CN112125881B (zh) | 2019-06-25 | 2020-06-24 | 4-吡啶取代酞嗪酮类化合物、其制备方法、药物组合物及用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN112125881B (zh) |
WO (1) | WO2020259539A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112778333B (zh) * | 2021-01-23 | 2022-07-05 | 中国科学院新疆理化技术研究所 | 一种四氢噁唑并吡啶并氮氧杂酮类衍生物及其用途 |
CN115044100B (zh) * | 2022-07-20 | 2023-05-02 | 广东粤港澳大湾区黄埔材料研究院 | 离子液体阻燃剂及其制备方法和聚酰胺材料 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011055270A1 (en) * | 2009-11-04 | 2011-05-12 | Wyeth Llc | Indole based receptor crth2 antagonists |
CN104887680A (zh) * | 2015-05-08 | 2015-09-09 | 胡继承 | 多聚adp核糖聚合酶抑制剂治疗乙肝病毒相关疾病的新用途 |
CN106467495A (zh) * | 2015-08-19 | 2017-03-01 | 中国科学院上海药物研究所 | 哒嗪酮类化合物、其制备方法、药物组合物及用途 |
ES2905926T3 (es) * | 2017-08-10 | 2022-04-12 | Shanghai Inst Materia Medica Cas | Derivados de ftalazinona, método para la preparación de los mismos, composición farmacéutica que los comprende y su uso |
CN109384727B (zh) * | 2017-08-10 | 2023-07-28 | 中国科学院上海药物研究所 | 酞嗪酮类化合物、其制备方法、药物组合物及用途 |
-
2020
- 2020-06-24 WO PCT/CN2020/097944 patent/WO2020259539A1/zh active Application Filing
- 2020-06-24 CN CN202010600646.9A patent/CN112125881B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN112125881A (zh) | 2020-12-25 |
WO2020259539A1 (zh) | 2020-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3577118B1 (en) | Compounds for the treatment of hepatitis b virus infection | |
US10683299B2 (en) | Pyrazolopyrazine and triazolopyrazine compounds for the treatment of infectious diseases | |
EP3458455B1 (en) | Novel pyrazine compounds with oxygen, sulfur and nitrogen linker for the treatment of infectious diseases | |
JP5763126B2 (ja) | 抗ウイルス化合物 | |
CN102725302B (zh) | 2'-氟-6'-亚甲基碳环核苷和治疗病毒感染的方法 | |
CA2875690C (en) | Macrocyclic inhibitors of flaviviridae viruses | |
CN112125881B (zh) | 4-吡啶取代酞嗪酮类化合物、其制备方法、药物组合物及用途 | |
CN111018891B (zh) | 作为长效dpp-iv抑制剂的取代的氨基六元饱和杂脂环类 | |
JP2010532352A (ja) | 抗ウイルス化合物 | |
WO2015197006A1 (zh) | 一种取代的氨基酸硫酯类化合物、其组合物及应用 | |
KR20230002706A (ko) | 결정질 ret 억제제 | |
CN108530464B (zh) | 一种多靶点激酶抑制剂 | |
CN114555607A (zh) | 一类靶向蛋白质水解通路的功能分子及其制备和应用 | |
TWI616453B (zh) | Substituted amino acid thioester compounds, compositions and uses thereof | |
CN109535200A (zh) | 一种核苷类似物的磷酰胺酯前药、药物组合物及其应用 | |
CN115197164A (zh) | 新型噻唑类化合物及其制备方法和用途 | |
CN114605417A (zh) | 双酰胺吡啶类化合物,其药物组合物、制备方法和应用 | |
CN117343064A (zh) | 一种具有抗病毒作用的嘧啶衍生物的制备与应用 | |
TW201706279A (zh) | 經取代的氨基磷酸酯類衍生物、其製備方法及其應用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |